Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian E Serfling

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
Clinical Nuclear Medicine|December 11, 2023
C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Hematological Malignancies-Myeloablative Effects, Antilymphoma Activity, and Safety ProfileNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Clinical Nuclear Medicine|April 19, 2022
Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor-Directed Molecular Imaging and TherapySebastian E Serfling, Philipp E Hartrampf, Yingjun Zhi, et al.
Clinical Nuclear Medicine|May 5, 2025
Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple MyelomaNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Nuklearmedizin. Nuclear Medicine|January 14, 2022
[18F]DCFPyL PET/CT for Imaging of Prostate CancerSteven P Rowe, Andreas Buck, Ralph A Bundschuh, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 5, 2023
Molecular imaging of arterial fibroblast activation protein: association with calcified plaque burden and cardiovascular risk factorsAleksander Kosmala, Sebastian E Serfling, Kerstin Michalski, et al.
Clinical Nuclear Medicine|February 8, 2023
Somatostatin Receptor-Directed PET/CT for Therapeutic Decision-Making and Disease Control in Patients Affected With Small Cell Lung CancerSebastian E Serfling, Philipp E Hartrampf, Yingjun Zhi, et al.
Clinical Nuclear Medicine|November 10, 2022
Impact of 68 Ga-FAPI-04 PET/CT on Staging and Therapeutic Management in Patients With Digestive System TumorsAleksander Kosmala, Sebastian E Serfling, Wiebke Schlötelburg, et al.
Clinical Nuclear Medicine|March 5, 2025
Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple MyelomaNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Clinical Nuclear Medicine|May 11, 2023
Impact of CXCR4-Directed PET/CT on Staging and Proposed Oncologic Management in Patients With Digestive System TumorsAlexander Weich, Sebastian E Serfling, Wiebke Schlötelburg, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 19, 2022
mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decreasePhilipp E Hartrampf, Ralph A Bundschuh, Franz-Xaver Weinzierl, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
Clinical Nuclear Medicine|December 11, 2023
C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Hematological Malignancies-Myeloablative Effects, Antilymphoma Activity, and Safety ProfileNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Clinical Nuclear Medicine|April 19, 2022
Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor-Directed Molecular Imaging and TherapySebastian E Serfling, Philipp E Hartrampf, Yingjun Zhi, et al.
Clinical Nuclear Medicine|May 5, 2025
Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple MyelomaNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Nuklearmedizin. Nuclear Medicine|January 14, 2022
[18F]DCFPyL PET/CT for Imaging of Prostate CancerSteven P Rowe, Andreas Buck, Ralph A Bundschuh, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 5, 2023
Molecular imaging of arterial fibroblast activation protein: association with calcified plaque burden and cardiovascular risk factorsAleksander Kosmala, Sebastian E Serfling, Kerstin Michalski, et al.
Clinical Nuclear Medicine|February 8, 2023
Somatostatin Receptor-Directed PET/CT for Therapeutic Decision-Making and Disease Control in Patients Affected With Small Cell Lung CancerSebastian E Serfling, Philipp E Hartrampf, Yingjun Zhi, et al.
Clinical Nuclear Medicine|November 10, 2022
Impact of 68 Ga-FAPI-04 PET/CT on Staging and Therapeutic Management in Patients With Digestive System TumorsAleksander Kosmala, Sebastian E Serfling, Wiebke Schlötelburg, et al.
Clinical Nuclear Medicine|March 5, 2025
Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple MyelomaNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Clinical Nuclear Medicine|May 11, 2023
Impact of CXCR4-Directed PET/CT on Staging and Proposed Oncologic Management in Patients With Digestive System TumorsAlexander Weich, Sebastian E Serfling, Wiebke Schlötelburg, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 19, 2022
mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decreasePhilipp E Hartrampf, Ralph A Bundschuh, Franz-Xaver Weinzierl, et al.
Pageof 8